An update on CELMoDs in myeloma: the promising activity and safety of iberdomide & mezigdomide

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, provides an update on cereblon E3 ligase modulators (CELMoDs) for the treatment of multiple myeloma (MM), mentioning the promising efficacy and favorable safety profile of iberdomide. Dr Richardson also discusses the potential of mezigdomide, highlighting its ability to fully close the cereblon E3 ligase complex, leading to rapid and intense degradation of key transcription factors. This agent has shown encouraging results in combination strategies, including with proteasome inhibitors, monoclonal antibodies, and novel agents, such as trametinib. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео An update on CELMoDs in myeloma: the promising activity and safety of iberdomide & mezigdomide канала VJHemOnc – Video Journal of Hematology & HemOnc